These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7058319)

  • 1. [Behavior of high-density lipoproteins in drug lipid-lowering treatment].
    Mordasini R; Riesen W; Oster P; Riva G
    Schweiz Med Wochenschr; 1982 Jan; 112(3):95-8. PubMed ID: 7058319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG; Hutt V; Klör HU; Ditschuneit H
    Artery; 1980; 8(6):519-29. PubMed ID: 7259531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
    Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of pravastatin on serum lipids, apoproteins, and lipoprotein (a) in primary hypercholesterolemia].
    Galetta F; Sampietro T; Basta G; Bionda A
    Minerva Med; 1994 Jun; 85(6):321-6. PubMed ID: 8084435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. I. Effect on cholesterol, lipid and apoprotein levels].
    Sznajd J; Idzior-Waluś B; Zabiński J; Wybrańska I; Korzus G; Iwanejko J
    Przegl Lek; 1990; 47(10):706-10. PubMed ID: 2089449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S; Pogarell O; Keller C; Wolfram G
    Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W; Davidson MH; Kulkarni PM; Siddhanti S; Ciaccia AV; Keech CA
    Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of garlic on lipid profile and psychopathologic parameters in people with mild to moderate hypercholesterolemia.
    Peleg A; Hershcovici T; Lipa R; Anbar R; Redler M; Beigel Y
    Isr Med Assoc J; 2003 Sep; 5(9):637-40. PubMed ID: 14509153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of lovastatin on serum lipids and lipoproteins. Hungarian multicenter, open-label study].
    Romics L; Karádi I; Csanády M; Gógl A; Jánosi A; Ofner P; Tarján J; Varga L; Wórum F; Zeltner G
    Orv Hetil; 1994 Oct; 135(40):2187-91. PubMed ID: 7970631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect on lipids, lipoproteins and apoproteins of labetalol prescribed in doses of 400 mg/day in hypertensive patients. Double-blind versus placebo study].
    Rouffy J; Bakir R; Chanu B; Djian F; Goy-Loeper J; Henry Amar M; Renon D; Pappo M
    Pathol Biol (Paris); 1986 Apr; 34(4):253-8. PubMed ID: 3529000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.